Prevention of atrial fibrillation in patients with symptomatic chronic heart failure by candesartan in the Candesartan in Heart failure: assessment of Reduction in Mortality and morbidity (CHARM) program

American Heart Journal
Anique DucharmeSalim Yusuf

Abstract

Atrial fibrillation (AF) is frequent in patients with chronic heart failure (CHF). Experimental and small patient studies have demonstrated that blocking the renin-angiotensin-aldosterone system may prevent AF. In the CHARM program, the effects of the angiotensin receptor blocker candesartan on cardiovascular mortality and morbidity were evaluated in a broad spectrum of patients with symptomatic CHF. CHARM provided the opportunity to prospectively determine the effect of candesartan on the incidence of new AF in this CHF population. 7601 patients with symptomatic CHF and reduced or preserved left ventricular systolic function were randomized to candesartan (target dose 32 mg once daily, mean dose 24 mg) or placebo in the 3 component trials of CHARM. The major outcomes were cardiovascular death or CHF hospitalization and all-cause mortality. The incidence of new AF was a prespecified secondary outcome. Median follow-up was 37.7 months. A conditional logistic regression model for stratified data was used. 6446 patients (84.8%) did not have AF on their baseline electrocardiogram. Of these, 392 (6.08%) developed AF during follow-up, 177 (5.55%) in the candesartan group and 215 (6.74%) in the placebo group (odds ratio 0.812, 95% CI ...Continue Reading

References

Nov 15, 1995·Journal of the American College of Cardiology·W G StevensonJ A Walden
Jul 1, 1994·Journal of Molecular and Cellular Cardiology·C G BrillaK T Weber
Sep 15, 1993·Proceedings of the National Academy of Sciences of the United States of America·G PagèsJ Pouysségur
Nov 15, 1996·Journal of the American College of Cardiology·W G StevensonJ H Tillisch
Jun 2, 2001·The New England Journal of Medicine·M PackerUNKNOWN Carvedilol Prospective Randomized Cumulative Survival Study Group
Jun 25, 2003·Journal of the American College of Cardiology·Koichiro KumagaiKeijiro Saku
Sep 19, 2003·Lancet·Marc A PfefferUNKNOWN CHARM Investigators and Committees
May 18, 2004·The American Journal of Cardiology·Mihai Gheorghiade, Mary Ann Lukas
Dec 3, 2004·The New England Journal of Medicine·Li-Fern HsuMichel Haïssaguerre

❮ Previous
Next ❯

Citations

Feb 12, 2008·Journal of Interventional Cardiac Electrophysiology : an International Journal of Arrhythmias and Pacing·Rangadham Nagarakanti, Michael Ezekowitz
Mar 5, 2008·Journal of Interventional Cardiac Electrophysiology : an International Journal of Arrhythmias and Pacing·Maya GuglinAnne B Curtis
Mar 26, 2008·Journal of Interventional Cardiac Electrophysiology : an International Journal of Arrhythmias and Pacing·Michael R RosenMatthias J Szabolcs
Aug 10, 2007·Current Hypertension Reports·Kristian WachtellAnd Paulette A Lyle
Sep 4, 2008·Current Hypertension Reports·Tonje A AksnesSverre E Kjeldsen
Sep 26, 2007·Nature Clinical Practice. Cardiovascular Medicine·Richard N Re, Julia L Cook
Apr 17, 2009·The New England Journal of Medicine·Marcello DisertoriGianni Tognoni
Dec 9, 2008·British Medical Bulletin·Abhay BajpaiA John Camm
Oct 30, 2009·Europace : European Pacing, Arrhythmias, and Cardiac Electrophysiology : Journal of the Working Groups on Cardiac Pacing, Arrhythmias, and Cardiac Cellular Electrophysiology of the European Society of Cardiology·C LeclercqUNKNOWN CHAMP Study Investigators
Jan 13, 2010·Europace : European Pacing, Arrhythmias, and Cardiac Electrophysiology : Journal of the Working Groups on Cardiac Pacing, Arrhythmias, and Cardiac Cellular Electrophysiology of the European Society of Cardiology·Dimpi PatelAndrea Natale
Feb 25, 2011·Europace : European Pacing, Arrhythmias, and Cardiac Electrophysiology : Journal of the Working Groups on Cardiac Pacing, Arrhythmias, and Cardiac Cellular Electrophysiology of the European Society of Cardiology·Irene SavelievaA John Camm
Jul 28, 2011·Europace : European Pacing, Arrhythmias, and Cardiac Electrophysiology : Journal of the Working Groups on Cardiac Pacing, Arrhythmias, and Cardiac Cellular Electrophysiology of the European Society of Cardiology·Paulus KirchhofA John Camm
Jan 13, 2010·Circulation Journal : Official Journal of the Japanese Circulation Society·Nobuhisa Hagiwara
Oct 22, 2010·Circulation Journal : Official Journal of the Japanese Circulation Society·UNKNOWN JCS Joint Working Group
Feb 16, 2010·Nihon yakurigaku zasshi. Folia pharmacologica Japonica·Koichiro Kumagai
May 14, 2009·Vascular Health and Risk Management·Jean-Philippe BaguetYannick Neuder
Dec 31, 2010·Vascular Health and Risk Management·Maria Leonarda De Rosa
Jun 9, 2010·American Journal of Cardiovascular Drugs : Drugs, Devices, and Other Interventions·Concepción MoroRoberto Matía
Jun 8, 2012·High Blood Pressure & Cardiovascular Prevention : the Official Journal of the Italian Society of Hypertension·Claudio Borghi, Arrigo F G Cicero
Dec 18, 2009·Future Cardiology·Khaja S MohammedSimone Musco
Jul 1, 2007·Future Cardiology·Giuliano TocciMassimo Volpe
May 16, 2014·Archives of Medical Research·Jun ZhaoGuangping Li
Dec 19, 2013·European Heart Journal·Sarah C W MarottBørge G Nordestgaard
Jun 3, 2009·Current Heart Failure Reports·Marcelle D SmitDirk J van Veldhuisen
Aug 6, 2014·American Journal of Cardiovascular Drugs : Drugs, Devices, and Other Interventions·Abhishek MaanE Kevin Heist
Aug 15, 2009·International Journal of Hyperthermia : the Official Journal of European Society for Hyperthermic Oncology, North American Hyperthermia Group·Naohiko TakahashiT Saikawa
Nov 15, 2011·Expert Opinion on Pharmacotherapy·Maurizio DestroEmilio Galli
Mar 20, 2009·Expert Review of Cardiovascular Therapy·Wanwarang Wongcharoen, Shih-Ann Chen
Jul 11, 2009·Expert Review of Cardiovascular Therapy·Marcelle D Smit, Isabelle C Van Gelder
May 27, 2009·Expert Opinion on Pharmacotherapy·Silvia BarraGiovanni Gaeta
Jun 10, 2011·Expert Opinion on Pharmacotherapy·Alexander JoostPeter Walter Radke
Jul 1, 2009·Expert Opinion on Pharmacotherapy·B Mendis, S R Page
Jun 20, 2013·Blood Pressure·UNKNOWN Task Force for the management of arterial hypertension of the European Society of Hypertension, UNKNOWN Task Force for the management of arterial hypertension of the European Society of Cardiology
Dec 8, 2015·Circulation Journal : Official Journal of the Japanese Circulation Society·Takeshi YamauchiUNKNOWN CHART-2 Investigators
Mar 25, 2014·Heart Failure Clinics·Sudarone Thihalolipavan, Daniel P Morin

❮ Previous
Next ❯

Related Concepts

Related Feeds

Atrial Filbrillation

Atrial fibrillation refers to the abnormal heart rhythm characterized by rapid and irregular beating of the atria. Here is the latest research.

Antihypertensive Agents: Mechanisms of Action

Antihypertensive drugs are used to treat hypertension (high blood pressure) which aims to prevent the complications of high blood pressure, such as stroke and myocardial infarction. Discover the latest research on antihypertensive drugs and their mechanism of action here.

Anti-Arrhythmic Drug Therapies

Anti-arrhythmic drugs are used to prevent abnormal heart rhythms. These medications are used in conditions including, ventricular tachycardia, ventricular fibrillation and atrial fibrillation. Discover the latest research on anti-arrhythmic drug therapies here.

Anthelmintics

Anthelmintics or antihelminthics are a group of antiparasitic drugs that expel parasitic worms (helminths) and other internal parasites from the body by either stunning or killing them and without causing significant damage to the host. Discover the latest research on anthelmintics here.

Atrial Fibrillation

Atrial fibrillation is a common arrhythmia that is associated with substantial morbidity and mortality, particularly due to stroke and thromboembolism. Here is the latest research.

Arrhythmia

Arrhythmias are abnormalities in heart rhythms, which can be either too fast or too slow. They can result from abnormalities of the initiation of an impulse or impulse conduction or a combination of both. Here is the latest research on arrhythmias.

Antiarrhythmic Agents: Mechanisms of Action

Understanding the mechanism of action of antiarrhythmic agents is essential in developing new medications as treatment of cardiac arrhythmias is currently limited by the reduced availability of safe and effective drugs. Discover the latest research on Antiarrhythmic Agents: Mechanism of Action here.